

C. DIFFICILE INFECTION (CDI)— A VICIOUS CYCLE OF RECURRENCE THAT RESULTS IN A SIGNIFICANT BURDEN^{1,2}

APPROXIMATELY HALF A MILLION CDI CASES
IN THE UNITED STATES ANNUALLY^{2,3}

RECURRENT CDI (rCDI) AFFECTS PATIENT QUALITY OF LIFE
AND HOSPITAL QUALITY METRICS AND REIMBURSEMENT

Recurrence: Up to 35%^{3,4,a}

Re-recurrence: Up to 60%⁵

Sepsis: 27%⁶

Colectomy: 7%⁶

Heart failure: 43%⁷

Mortality: 6%³

Mortality in patients with
COVID-19 and CDI: 44%⁸

Up to 85% of all patients with rCDI
were hospitalized in 12 months⁹

57% of patients with at least one CDI
recurrence experienced **≥2 hospital
admissions** within 12 months⁷

Hospitalizations average 18 days
for patients with rCDI⁷

84% of patients with
rCDI are readmitted⁹

–\$3K to –\$29K gap exists in
reimbursement per patient¹⁰

\$131K to \$207K comprised total
cost of a patient with rCDI²

BREAK THE CYCLE



LEARN MORE ABOUT BREAKING THE
CYCLE OF *C. DIFF* RECURRENCE AT
POWEROFMICROBIOME.COM



Antibiotics are the standard of care for the treatment of *C. diff* and effective for some. However, their use has been shown to disrupt the ecology of the gut microbiome and are a predominant risk factor for CDI recurrence.¹¹

^aWithin 8 weeks after initial *C. diff* infection diagnosis.³

References: 1. Centers for Disease Control and Prevention. <https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf>. Accessed June 24, 2020. 2. Feuerstadt P, et al. *J Med Econ*. 2020;23(6):603-609. 3. Lessa FC, et al. *N Engl J Med*. 2015;372(9):825-834. 4. Cornely OA, et al. *Clin Infect Dis*. 2012;55(suppl 2):s154-s161. 5. Leong C, Zelenitsky S. *Can J Hosp Pharm*. 2013;66(6):361-368. 6. Feuerstadt P, et al. *SAGE Open Med*. 2021;9:2050312120986733. doi: 10.1177/2050312120986733. 7. Nelson WW, et al. [published online March 11, 2021]. *J Manag Care Spec Pharm*. 2021;1-11. doi:10.18553/jmcp.2021.20395. 8. Sandhu A, et al. [published online May 22, 2020]. *Emerg Infect Dis*. 2020;26(9):10.3201/eid2609.202126. doi:10.3201/eid2609.202126. 9. Rodrigues R, et al. *Infect Control Hosp Epidemiol*. 2017;38(2):196-202. 10. Zilberberg MD, et al. *Medicine*. 2018;97(36):e12212. doi:10.1097/MD.00000000000012212. 11. McDonald LC, et al. *Clin Infect Dis*. 2018;66(7):e1-e48.

FERRING
PHARMACEUTICALS

Microbiome
Therapeutics
Development